Back to resultsTherapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Primary Purpose
Cutaneous T-cell Lymphoma (CTCL)
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Sirolimus 0.1% Ointment
Sponsored by
About this trial
This is an interventional treatment trial for Cutaneous T-cell Lymphoma (CTCL) focused on measuring Early stage, Stage 1A, Cutaneous T-cell Lymphoma, CTCL
Eligibility Criteria
Inclusion Criteria:
- Clinically and histologically confirmed diagnosis of CTCL (early stage disease with patches and/or thin plaques covering up to 10%, stage IA)
- Relapsed or refractory disease after at least one standard skin directed treatment including corticosteroids, topical bexarotene, phototherapy
- All subjects must be 18 years of age or older
- Life expectancy ≥ 6 months, determined by the treating physician
- Signed informed consent
Exclusion Criteria:
- Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including topical or systemic glucocorticosteroids, chemotherapy, radiation therapy, antibody based therapy, etc.)
- Prior treatment with any investigational drug within the preceding 4 weeks
- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.
- Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Adequate contraception (oral contraceptives ("the pill"), intrauterine devices (IUDs), contraceptive implants under the skin, or contraceptive injections, diaphragms with spermicide and condoms with foam) must be used throughout the trial and for 8 weeks after the last dose of study drug (women of childbearing potential must have a negative urine within 7 days prior to administration of sirolimus).
- Patients who have received prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, everolimus).
- Patients with a known hypersensitivity to sirolimus or other rapamycin (e.g., everolimus, temsirolimus) or to its excipient
- History of noncompliance to medical regimens
- Patients unwilling to or unable to comply with the protocol
Sites / Locations
- Froedtert Hospital and the Medical College of Wisconsin
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sirolimus 0.1% ointment
Arm Description
Sirolimus 0.1% ointment
Outcomes
Primary Outcome Measures
Overall Response Rate
Determine the efficacy of topical sirolimus in the treatment of early stage CTCL as overall response rate (ORR)
Response criteria:
Complete response (CR) will be defined as no evidence of clinical skin disease.
Partial response (PR) will be defined as a marked improvement in skin disease of > 50% from baseline without new lesions.
Stable disease (SD) will be defined as < 25% increase and < 50% clearance in skin disease from baseline without new lesions.
Progressive disease (PD) will be defined as > 25% increase in skin disease from baseline or new tumors or loss of response in those with CR or PR (increase in skin score of greater than the sum of nadir plus 50% baseline score).
The assessment will be based on Composite Assessment of Index Lesion Severity (CAILS) and, in case of more extensive disease, Modified Severity-Weighed Assessment Tool (mSWAT) scores.
Secondary Outcome Measures
Duration of objective response (DOR)
Duration of objective response (DOR) - time from the first date of response until progression of disease or death due to the underlying lymphoma.
Adverse event profile and tolerability of topical sirolimus in patients with CTCL
The safety and tolerability of the study treatment regimen will be evaluated. Analyses will be descriptive and no formal hypothesis testing will be performed.
Safety endpoints will include treatment related adverse events. All reported adverse events will be graded using version 4.0 of the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
All adverse events recorded during the study will be summarized. The incidence of adverse events will be summarized by body system, severity (based on CTCAE grades), type of adverse event, and relation to the study drug. Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and type of adverse event. Adverse events will be summarized by presenting the number and percentage of patients having any adverse event in each body system and having each individual adverse event.
Correlative biomarkers such as mTOR pathway activation at baseline and during treatment
• Activation level of the mammalian target of rapamycin (mTOR) pathway, quantification of regulatory T cells (Tregs), cytokine profile in tissue samples. This part of the study will characterize the molecular events and mechanisms involved in the effect of sirolimus on CTCL. These studies will be performed in tissues samples from skin biopsies of patients upon study entry and during the study.
mTOR pathway activity in skin:
Assessment of phosphorylation status and expression level of downstream targets of mTOR with direct effects on cellular proliferation and growth. Those may include:
phospho-S6
phospho-4-EBP1
cyclin D1 levels
Number of skin resident Tregs:
Quantification of regulatory T cells characterized by surface marker expression pattern (CD4+, CD25+, FOXP3+) in tissue samples by immunohistochemistry and/or PCR/flow cytometry.
Cytokine profile in skin:
Characterization of cytokine profile in lesional skin will be done by cytokine PCR arrays.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01843998
Brief Title
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Official Title
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Withdrawn
Study Start Date
February 2014 (undefined)
Primary Completion Date
May 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Stefan Schieke MD
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether sirolimus reduces the symptoms of cutaneous T-cell lymphoma (CTCL) and whether it causes any side effects.
Detailed Description
This will be a prospective, non-randomized, open label study of topical sirolimus for the treatment of CTCL recurrent or refractory to at least one previous skin directed treatment. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations.
Study duration:
For subjects with at least partial remission, treatment will be continued for a maximum of 6 months. All subjects will be followed for 6 months from the time of discontinuation of the study drug or until progression of disease or until a new treatment for CTCL will be started.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cutaneous T-cell Lymphoma (CTCL)
Keywords
Early stage, Stage 1A, Cutaneous T-cell Lymphoma, CTCL
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sirolimus 0.1% ointment
Arm Type
Experimental
Arm Description
Sirolimus 0.1% ointment
Intervention Type
Drug
Intervention Name(s)
Sirolimus 0.1% Ointment
Other Intervention Name(s)
Rapamune, sirolimus, rapamycin
Intervention Description
Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
Primary Outcome Measure Information:
Title
Overall Response Rate
Description
Determine the efficacy of topical sirolimus in the treatment of early stage CTCL as overall response rate (ORR)
Response criteria:
Complete response (CR) will be defined as no evidence of clinical skin disease.
Partial response (PR) will be defined as a marked improvement in skin disease of > 50% from baseline without new lesions.
Stable disease (SD) will be defined as < 25% increase and < 50% clearance in skin disease from baseline without new lesions.
Progressive disease (PD) will be defined as > 25% increase in skin disease from baseline or new tumors or loss of response in those with CR or PR (increase in skin score of greater than the sum of nadir plus 50% baseline score).
The assessment will be based on Composite Assessment of Index Lesion Severity (CAILS) and, in case of more extensive disease, Modified Severity-Weighed Assessment Tool (mSWAT) scores.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Duration of objective response (DOR)
Description
Duration of objective response (DOR) - time from the first date of response until progression of disease or death due to the underlying lymphoma.
Time Frame
6 months
Title
Adverse event profile and tolerability of topical sirolimus in patients with CTCL
Description
The safety and tolerability of the study treatment regimen will be evaluated. Analyses will be descriptive and no formal hypothesis testing will be performed.
Safety endpoints will include treatment related adverse events. All reported adverse events will be graded using version 4.0 of the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
All adverse events recorded during the study will be summarized. The incidence of adverse events will be summarized by body system, severity (based on CTCAE grades), type of adverse event, and relation to the study drug. Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and type of adverse event. Adverse events will be summarized by presenting the number and percentage of patients having any adverse event in each body system and having each individual adverse event.
Time Frame
6 months
Title
Correlative biomarkers such as mTOR pathway activation at baseline and during treatment
Description
• Activation level of the mammalian target of rapamycin (mTOR) pathway, quantification of regulatory T cells (Tregs), cytokine profile in tissue samples. This part of the study will characterize the molecular events and mechanisms involved in the effect of sirolimus on CTCL. These studies will be performed in tissues samples from skin biopsies of patients upon study entry and during the study.
mTOR pathway activity in skin:
Assessment of phosphorylation status and expression level of downstream targets of mTOR with direct effects on cellular proliferation and growth. Those may include:
phospho-S6
phospho-4-EBP1
cyclin D1 levels
Number of skin resident Tregs:
Quantification of regulatory T cells characterized by surface marker expression pattern (CD4+, CD25+, FOXP3+) in tissue samples by immunohistochemistry and/or PCR/flow cytometry.
Cytokine profile in skin:
Characterization of cytokine profile in lesional skin will be done by cytokine PCR arrays.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinically and histologically confirmed diagnosis of CTCL (early stage disease with patches and/or thin plaques covering up to 10%, stage IA)
Relapsed or refractory disease after at least one standard skin directed treatment including corticosteroids, topical bexarotene, phototherapy
All subjects must be 18 years of age or older
Life expectancy ≥ 6 months, determined by the treating physician
Signed informed consent
Exclusion Criteria:
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including topical or systemic glucocorticosteroids, chemotherapy, radiation therapy, antibody based therapy, etc.)
Prior treatment with any investigational drug within the preceding 4 weeks
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Adequate contraception (oral contraceptives ("the pill"), intrauterine devices (IUDs), contraceptive implants under the skin, or contraceptive injections, diaphragms with spermicide and condoms with foam) must be used throughout the trial and for 8 weeks after the last dose of study drug (women of childbearing potential must have a negative urine within 7 days prior to administration of sirolimus).
Patients who have received prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, everolimus).
Patients with a known hypersensitivity to sirolimus or other rapamycin (e.g., everolimus, temsirolimus) or to its excipient
History of noncompliance to medical regimens
Patients unwilling to or unable to comply with the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Schieke, MD
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Froedtert Hospital and the Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
We'll reach out to this number within 24 hrs